subject: Role Of Manufacturing In Biologics Industry [print this page] Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
The report provides the key data and analyzes the major challenges and drivers for the bio-manufacturing industry. The report also analyzes the strengths, weaknesses of and opportunities for the stakeholders in the manufacturing of biologics. The report also discusses the key market drivers and barriers for the growth of bio-manufacturing in the pharmaceutical and biotech industry. ( http://www.bharatbook.com/detail.asp?id=149187&rt=Manufacturing-of-Biologics-Increasing-Demand-for-Monoclonal-Antibodies-and-Recombinant-Proteins-Drives-Increases-in-Capacities-and-Innovative-Production-Technologies.html )
The Global Biologics Industry Has Grown More Rapidly Than the Global Pharmaceutical Industry
The biologics industry has emerged as a major growth area in the global healthcare industry. Since its emergence in the 1970s, the biologics industry has grown rapidly to reach approximately $128 billion in 2009. This analysis suggests that the biologics drugs market has outperformed the pharmaceutical market in the past few years. The biologics industry had a year on year average growth rate of approximately 11.5% over the period of 20072009. This is significantly higher than the pharmaceutical industrys growth rate of 6% in the same time period. It is expected to grow by 9.3% for the period of 20092016.
Strong Growth is expected in the CMO Biologics Market
The use of CMOs is one of the most significant trends in the healthcare industry, especially in the biologics market. CMOs will be used for most of the processes in the industry. Although the CMO market is not growing much at the moment due to capacity expansions by major companies such as Lonza Group Ltd., Boehringer Ingelheim (BI), and many more. Their focus has been shifted towards setting up new plants, buying new equipments. These expansion processes indicate the future prospects of the industry. Many experts in the industry have already predicted that the future of the CMO market is bright. Several players from emerging countries are entering the market. Companies are opening up beginning operations in emerging countries such as India, China, and Singapore.
The market shares of CMOs the developed countries are expected to decline in the coming years due to the high cost of operations and due to the development taking place in the emerging markets. The share of the emerging markets is expected to more than double by 2013 and to triple by 2016.
Biologics Manufacturing Capacity and Production
Biologics manufacturing is expected to grow in the near future. Most of the biologics companies are expanding their manufacturing facilities throughout the world. New companies are coming into the market and many pharmaceutical companies are now manufacturing biologics.
Currently, the capacity in the industry is more than the production. The major reasons for this are the low capacity utilization rate and low demand.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149187&rt=Manufacturing-of-Biologics-Increasing-Demand-for-Monoclonal-Antibodies-and-Recombinant-Proteins-Drives-Increases-in-Capacities-and-Innovative-Production-Technologies.html
Related Reports
Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025
